Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category

Abstract:
NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today it has been awarded the "Young Talent" Award at the INVESTOR AWARDS 2013, referring to a newly listed company.

NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category

Paris, France | Posted on November 8th, 2013

Nanobiotix was judged as the company, outside of the CAC 40, that achieved the most successful and most promising IPO of the year. The Company came first in this category for successfully meeting the main criteria: corporate profile, leadership in its business activity and financial health.

"It is an honor to receive this award from the Investor Awards panel," said Laurent Levy, CEO and co-founder of Nanobiotix. "This award reflects the success of the Nanobiotix IPO in October 2012, where many investors showed an interest in our breakthrough technology in nanomedicine for local cancer treatment. We remain focused on the clinical development of our products, which positions us as a leader in nanomedicine. We are also preparing for the challenges around the marketing of our lead product, NBTXR3, which could occur in 2017."

This prize was awarded by Boursorama and Morningstar that jointly organize the largest survey that selects listed companies by individual and professional investors' preferences.

The online survey was conducted with investors by OpinionWay in May 2013. In total, more than 40,000 votes were collected (two-thirds of individuals and a third of professionals).

####

About Nanobiotix
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration.

Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma and locally advanced head and neck cancer. The Company, based in Paris, France, has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

For more information, please click here

Contacts:
Nanobiotix

Sarah Gaubert
Head of Communication
and Public Affairs
+33 (0)1 40 26 07 55


Yucatan
Media relations (France)
Annie-Florence Loyer/ Nadège Le Lezec
+33 (0)1 53 63 27 27
+33 (0)6 88 20 35 59


NewCap.
Financial communication
and investors relations
Louis-Victor Delouvrier / Emmanuel Huynh
+33 (0)1 44 71 98 53


College Hill
Media relations (Outside France)
Melanie Toyne Sewell / Donia Al Saffar
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Rice U. chemists create 3-D printed graphene foam June 22nd, 2017

Tiny bubbles provide tremendous propulsion in new microparticles research-Ben-Gurion U. June 21st, 2017

Enhanced photocatalytic activity by Cu2O nanoparticles integrated H2Ti3O7 nanotubes June 21st, 2017

Researchers developed nanoparticle based contrast agent for dual modal imaging of cancer June 21st, 2017

Nanomedicine

Researchers developed nanoparticle based contrast agent for dual modal imaging of cancer June 21st, 2017

Learning with light: New system allows optical “deep learning”: Neural networks could be implemented more quickly using new photonic technology June 12th, 2017

Mussels add muscle to biocompatible fibers: Rice University chemists develop hydrogel strings using compound found in sea creatures June 9th, 2017

Making vessels leaky on demand could aid drug delivery:Rice University scientists use magnets and nanoparticles to open, close gaps in blood vessels June 8th, 2017

Announcements

Rice U. chemists create 3-D printed graphene foam June 22nd, 2017

Tiny bubbles provide tremendous propulsion in new microparticles research-Ben-Gurion U. June 21st, 2017

Enhanced photocatalytic activity by Cu2O nanoparticles integrated H2Ti3O7 nanotubes June 21st, 2017

Researchers developed nanoparticle based contrast agent for dual modal imaging of cancer June 21st, 2017

Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records

Rice U. chemists create 3-D printed graphene foam June 22nd, 2017

Mussels add muscle to biocompatible fibers: Rice University chemists develop hydrogel strings using compound found in sea creatures June 9th, 2017

The 2017 Winners for Generation Nano June 8th, 2017

Controlling 3-D behavior of biological cells using laser holographic techniques May 26th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project